

Correction to *Lancet Neurol* 2019; 18: 329–31



Azevedo CJ, Kutz C, Dix A, et al. Intracerebral haemorrhage during alemtuzumab administration. *Lancet Neurol* 2019; **18**: 329–31—In this Correspondence, Christina Azevedo and coauthors stated: “We have retrospectively identified another five cases of spontaneous intracranial haemorrhage that occurred during the initial 5-day course of alemtuzumab administration.” With the use of the word “another”, the statement implied that the five cases of intracranial haemorrhage described in their letter were in addition to 13 cases that had been reported to the FDA. However, those five cases were in fact among the 13 cases reported by the FDA. The sentence has been amended for clarity. This correction has been made to the online version as of July 8, 2019.

Published Online
July 8, 2019
[http://dx.doi.org/10.1016/S1474-4422\(19\)30251-0](http://dx.doi.org/10.1016/S1474-4422(19)30251-0)

Correction to *Lancet Neurol* 2019; 18: 653–65



Wilson D, Ambler G, Lee K-J, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. *Lancet Neurol* 2019; **18**: 653–65—In this Article, the upper bound of the 95% CI for the adjusted hazard ratio for ischaemic stroke for patients with 20 or more cerebral microbleeds has been corrected to 2.82 in the summary and table 2. This correction has been made to the online version as of July 12, 2019.

Published Online
July 12, 2019
[http://dx.doi.org/10.1016/S1474-4422\(19\)30276-5](http://dx.doi.org/10.1016/S1474-4422(19)30276-5)